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spondyloarthritis
Daniel E. Furst* and James S. Louie*Abstract
The triggers and pathogenesis of axial spondyloarthritis (axSpA) are not yet completely understood. However,
therapeutic agents targeting tumor necrosis factor-α and interleukin-17 inflammatory pathways have proven
successful in suppressing many of the clinical symptoms and signs of axSpA, giving us an indication of which
pathways are responsible for initiating and maintaining the inflammation. The mechanisms that eventuate in
syndesmophytes and ankyloses are less clear. This review addresses these two critical pathways of inflammation,
discussing their nature and these factors that may activate or enhance the pathways in patients with axSpA. In
addition, genetic and other markers important to the inflammatory pathways implicated in axSpA are explored, and
prognostic biomarkers are discussed. Treatment options available for the management of axSpA and their
associated targets are highlighted.
Keywords: Axial spondyloarthritis, Therapy, Inflammatory pathwaysBackground
Axial spondyloarthritis (axSpA) is the prototypical form
of a family of diseases known as spondyloarthritis (SpA)
characterized by inflammatory processes and new bone
formation [1, 2]. Inflammation, bone and cartilage loss,
and subsequent remodeling with new bone formation
take place in the entheses, axial skeleton, and peripheral
joints. Critically, axSpA encompasses two conditions: an-
kylosing spondylitis (AS), which presents with radio-
graphic damage and ankyloses of the sacroiliac joint (as
defined and validated by the Assessment of SpondyloAr-
thritis international Society [ASAS] classification cri-
teria) [3, 4], and nonradiographic axSpA (nr-axSpA),
which does not show radiographic changes but may de-
scribe inflammation to the sacroiliac joint by magnetic
resonance imaging (MRI), power Doppler ultrasound
(PDUS), or computed tomography [5, 6]. The prevalence
of axSpA in the USA is estimated to be 0.7%, with AS
and nr-axSpA each accounting for 0.35% of patients [7].
Patients with axSpA also present with a range of
extra-articular manifestations, including inflammatory
bowel lesions, psoriasis, and uveitis [1, 8, 9]. Thus,© The Author(s). 2019 Open Access This artic
International License (http://creativecommons
reproduction in any medium, provided you g
the Creative Commons license, and indicate if
(http://creativecommons.org/publicdomain/ze
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Department of Medicine, Division of Rheumatology, David Geffen School of
Medicine at UCLA, Los Angeles, CA, USAaxSpA is a potentially debilitating disease, associated
with chronic pain, deformities, and reduced function
and quality of life [10, 11].
The pathogenesis of axSpA appears to be multifactor-
ial, arising from several exogenous factors, engaging gen-
etic susceptibilities to amplify multiple inflammatory and
innate and acquired immune responses, and eventuating
in musculoskeletal damage and repair. Clinically, the ini-
tiating factors include biomechanical stresses affecting
the tissues and cells of the entheses, where tendons and
ligaments bind to the fibrocartilage and bone. McGona-
gle and colleagues [12] substantiated the concepts of
tissue micro-damage, whereby stresses in the syn-
ovial–entheseal complex trigger interleukin (IL)-23
from macrophages, dendritic cells, and possibly group
3 innate lymphoid cells (ILC3s) to initiate inflamma-
tion in the adjoining fibrocartilage, bursae, fat pad,
deep fascia, synovium, and cortical and trabecular
bone. The most stressed regions occur in the sacro-
iliac, spinal, sternoclavicular, manubriosternal, and
acromioclavicular joints, rather than in peripheral
joints [13, 14].
Another critical initiating factor may come from infec-
tious signals generated from commensal bacteria within
the gut microbiome, which moderate immune homeo-
stasis of the innate and innate-like cells at the barrierle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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monocytes, and dendritic cells permit expression of
IL-23 receptor-positive ILCs in the gut, blood, synovial
fluid, and bone marrow, and IL-23–positive cells in
spinal facet joints, which activate the IL-23/IL-17 axis of
pro-inflammatory cytokines [17, 18]. In addition, the
mechanisms that activate monocytes with lipopolysac-
charides (LPS) and other bacterial adjuvants and recruit
neutrophils to the entheses may be strong contributing
factors to both the production of tumor necrosis
factor-α (TNF) and the activation of osteoblasts [19].
Interestingly, increased levels of monocyte/macrophage
migration inhibition factor (MIF) in peripheral blood
correlate with disease activity and predict spinal syn-
desmophyte progression [20]. Furthermore, elevated
autoantibodies to the CD74 receptor for MIF are con-
sidered to be a diagnostic marker for axSpA, even in
patients who do not express human leukocyte antigen
(HLA)-B27 [21].
Susceptibility to axSpA in people with the HLA-B27
and HLA-B40 genes has been elegantly proposed; how-
ever, clear and consistent agreement across studies is
lacking. It is not clear whether HLA and non-HLA genes
and polymorphisms of the IL23R gene permit a lower
threshold of mechanical stress or LPS levels to be acti-
vated, although increased gut permeability has been pro-
posed. In addition, the chronic nature of the inflammatory
immune responses in axSpA may be due to aberrant pep-
tide processing and presentation, sustained triggering of
inflammatory pathways, and failure of inflammation to re-
solve in these HLA-B27 and HLA-B40 genetically predis-
posed individuals [9, 22]. Furthermore, what triggers and
maintains new bone formation and ankyloses in axSpA is
not fully understood, and it is not clear which therapeutic
modalities can clearly arrest the deformities caused by
new bone formation.
It is strongly suggested that the earliest therapies to
forestall inflammation will restrict damage and subse-
quent bone formation and ankyloses and thus allow pa-
tients to maintain function and quality of life. The latest
recommendations reinforce the concept of treating to-
wards defined and validated measures of disease activity,
as assessed by the Ankylosing Spondylitis Disease Activ-
ity Score (ASDAS), or the Bath Ankylosing Spondylitis
Disease Activity Index (BASDAI), recording improve-
ment based on achievement of ASAS20 or ASAS40, and
changing therapies if ASDAS scores do not indicate re-
mission (i.e., scores < 1.3) or ASAS partial remission
scores do not decrease by at least two units on a 0-to-10
scale in four domains. Secondly, clinical practice has
validated that therapeutic successes depend on the edu-
cated patient who has committed to mutually agreed--
upon goals with the rheumatologist, who regularly
communicates the clinical data [23–25].Methods
Targeted PubMed literature searches were conducted to
identify articles that discussed inflammatory pathways
and genes involved in the development of axSpA.
Searches were conducted using combinations of search
terms, including “ankylosing spondylitis,” “axial spondy-
loarthritis,” “inflammation,” “pathway,” “pathogenesis,”
“gene,” “biomarker,” “polymorphism,” “bone formation,”
“bone loss,” “comorbidities,” “IL-1,” “IL-6,” “IL-17,”
“IL-23,” and “TNF/tumor necrosis factor.” Search results
were supplemented based on the reference citations in
articles identified in initial searches and based on the au-
thors’ familiarity with the published literature. Articles
were qualitatively selected for inclusion in this review if
they presented results that the authors deemed relevant.
Therapies
The mainstay of pharmacologic treatment for both AS and
nr-axSpA begins with nonsteroidal anti-inflammatory drugs
(NSAIDs) [26], which inhibit the cyclooxygenase (COX) ac-
tivity of prostaglandin E2 (PGE2). PGE2 initiates inflamma-
tion by activating macrophages, mast cells, neutrophils, and
site-specific stromal and vascular endothelial cells and facili-
tates the transition from innate to acquired immune re-
sponses by enhancing the IL-23/IL-17 axis and developing
the regulatory T cell. Specifically, PGE2 acts on T-helper
(Th)1 and Th17 cells via its EP2 and EP4 receptors in the
presence of IL-1β and IL-23; receptor polymorphisms may
affect the efficacy of COX inhibitors in axSpA [27]. Inhibiting
PGE2 resolves entheseal inflammation, relieves pain, inhibits
vasodilation, and retards bone formation, particularly if used
continuously rather than intermittently, as confirmed by
ultrasound and x-rays [28, 29]. Thus, NSAID therapies are
strongly recommended [23, 25, 30].
The traditional disease-modifying anti-rheumatic
drugs (DMARDs), such as methotrexate, leflunomide,
and sulfasalazine, were not found to be effective in con-
trolling AS or nr-axSpA [26, 31]. However, analysis of
data from the Swedish Biologics Register showed that
the combination of conventional synthetic DMARDs
(especially methotrexate) with TNF inhibition enhances
retention to anti-TNF therapy [32].
Data from clinical trials have described that inhibitors
of IL-1 [33] and IL-6 [34], as well as therapy with abatacept
[35, 36] and rituximab (CD20) [37], did not appear to be
useful in AS. Rather, the current therapeutic approach that
is strongly recommended for the treatment of axSpA (re-
gardless of whether or not radiographic disease is present)
[26] centers on the use of biologic treatments directed at
more precise cytokine targets, including TNFα [11, 38–40]
and IL-23/IL-17 [41, 42]. Thus, we will address first the
TNF and IL-17 pathways, including the nature of the path-
ways, and the factors that may activate or enhance the
pathways in patients with axSpA or in animal models or
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important to the initial and then continuing inflammatory
pathways implicated in axSpA will be described, including
the sparse emerging data on prognostic biomarkers. Finally,
the range of treatment options available for the manage-
ment of axSpA and their associated targets will be
explored.
The inflammatory process: role of TNF and IL-17/
IL-23
Cytokines produced by various cells play an important
role in driving the immune response in axSpA and other
inflammatory arthritic diseases. Advances in molecular
and immunologic research over the past three decades
have repeatedly supported the key role of cytokine dys-
regulation in the pathophysiology of auto-inflammatory
and autoimmune diseases, including axSpA [9].
TNF
Several lines of evidence implicate TNF in the pathogen-
esis of axSpA; however, the exact TNF-associated cellular
and molecular mechanisms involved are not well under-
stood [2]. TNF, a 233 amino acid protein, is synthesized as
a transmembrane protein (tmTNF), in a trimeric form
which can be cleaved by a converting enzyme to a soluble
molecule (sTNF). Both act by binding to two receptors,
tumor necrosis factor receptor (TNFR) 1 and TNFR2, ac-
tivating multiple cellular pathways ranging from cell
homeostasis and proliferation via nuclear factor (NF)-κB
and protective immunity from infections and cell death
via the caspases, respectively (Fig. 1) [2]. Additionally,
tmTNF can act as a ligand by binding cell-to-cell to TNF
receptors and as a receptor that transmits reverse or
outside-to-inside signals to induce local inflammation
within the tmTNF-bearing cells. [43].
Key TNF signaling pathways include TNFR1 or TNFR
superfamily type 1A (TNFRSF1A), TNFR1-associated
death domain (TRADD), and TNFSF15 [1, 2, 44].
TNFR1 signaling is associated with NF-κB–mediated cell
survival and growth and/or apoptosis through the
TRADD adaptor protein [2]. TNFR2 is predomin-
antly produced by cells of immunologic and endo-
thelial origin, and is also associated with NF-κB
activation [2, 45]. Overexpression of TNF has been
documented in the sacroiliac joints of patients with
AS, and patients with AS have been shown to have
high levels of the circulating soluble TNF receptors
(sTNF-R1 and sTNF-R2) [46].
IL-23/IL-17 axis
Immunologic studies have strongly implicated the IL-23/
IL-17 axis in axSpA [2, 9]. Macrophages, dendritic cells,
ILCs, and mucosal-associated invariant T cells (MAITs)
contribute to elevated IL-23 levels found in the serum,inflamed gut, synovial fluid, entheses, and bone-derived
cells, including the marrow, and fibrous tissues taken
from the peripheral joints of patients with AS [47–52].
In addition, IL-17–positive mast cells and neutrophils
have been reported in facet joints [53], and IL-22 levels
have been shown to be elevated in the gut of patients
with AS [54]. Macrophages from patients with AS stim-
ulated by Toll-like receptor agonists such as LPS
produced IL-23; and IL-23 enhanced IL-17 production
from pathogenic Th17 cells [55].
In response to IL-23, additional cells, including CD4+
and CD8+ T cells in the microenvironment of other
pro-inflammatory cytokines, chemokines, and transcrip-
tional regulators (e.g., signal transducer and activation of
transcription [STAT] 3, RAR-related orphan receptor γt
[RORγt]), drive Th17 cells to produce IL-17 and other
cytokines, including IL-6, IL-22, IL-26, and TNF in a re-
ciprocating continuum [9, 56, 57]. The gut microbiome
may also contribute, as serum amyloid A from the ter-
minal ileum induces Th17 cell differentiation from naïve
CD4+ T lymphocytes, and microbiota-induced IL-1β
stimulates development of Th17 lymphocytes in the in-
testine [58].
Some have proposed that HLA-B27 misfolding and
homodimer formation triggers IL-23 and IL-17 produc-
tion through unfolded protein response and autophagy,
further supporting the link between the IL-23/IL-17
pathway and the development of axSpA [2, 59]. This
supports the emerging role of a pathogenic IL-23/IL-17
axis in axSpA [55, 60].
Genes and cytokines associated with axSpA
Extensive genome-wide association studies (GWAS) and
other studies have identified genes involved in the devel-
opment of axSpA, providing further insight into potential
therapeutic and diagnostic targets (Table 1) [2, 22, 61–63].
Axial spondyloarthritis appears to have high heritability,
not only in terms of susceptibility but also in determining
disease severity and functional incapacity [64]. The
gene-encoding HLA-B27, found within the major histo-
compatibility region, is the most well-established genetic
marker for axSpA [65–67]. Approximately 90% to 95% of
Caucasian patients with axSpA are positive for HLA-B27,
compared with only 6% to 8% of the general population
[68–71]. Wide ethnic variability in HLA-B27 expression
exists in patients with SpA [72]. Although the canonical
function of HLA-B27 is to present antigens to CD8+ T
cells, much of the altered innate immune response in
SpA may be related to cytoplasmic functions, which
prepare the peptide for effective presentation [1].
Thus, changes in the ubiquitination process, which
direct proteins to the subcellular proteasome and ami-
nopeptidase trimming of peptides, are important processes
that are associated with axSpA [73]. Indeed, endoplasmic
Fig. 1 Inflammatory Pathways in axSpA. In spondyloarthritis, biomechanical stress and inflammatory factors, including infectious antigens,
amplified by MHC susceptibility genes, HLA-B27 variants, and ERAP1 SNP transcription factors induce specific cell types to produce a series of
inflammatory cytokines, including IL-23, IL-17, TNF, IL-1, and IL-6. Hematopoietic stem cells elaborate NF-κB, RANKL, and M-CSF to differentiate
monocytes to osteoclasts, which extend inflammatory damage in the supporting structures of the sacroiliac and peripheral joints. Mesenchymal
stem cells facilitated by Wnt and BMP differentiate to osteoblasts to form new bone and ankyloses. BMP, bone morphogenetic protein; CRP,
C-reactive protein; DKK, Dickkopf; HLA, human leukocyte antigen; ERAP1, endoplasmic reticulum aminopeptidase 1; IL, interleukin; ILC-3s, group 3
innate lymphoid cells; M-CSF, monocyte colony-stimulating factor; MMP, metalloproteinase; NF-κB, nuclear factor-κB; OPG, osteoprotegerin; OSX,
osterix zinc finger-containing transcription factor; RANKL, receptor activator of nuclear factor-κB ligand; RUNX, runt-related transcription factor;
SFRP, secreted frizzled-related proteins; SNP, single-nucleotide polymorphism; SOX9, sex-determining region Y transcription factor; TNF, tumor
necrosis factor; VEGF, vascular endothelial growth factor. Italicized = transcription factor; red = inflammation; blue = bone formation/ankylosis.
Th1 cells = T helper cells for humoral immunity; Th17 cells = T helper cells for IL-17 inflammation, damage
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been associated with axSpA, with ERAP1 conferring a rela-
tive attributable risk to AS of approximately 25% [74].
One review identified more than 41 genes predisposing
to AS [75]. A meta-analysis identified 905 differentially
expressed genes in AS, which included 482 upregulated
genes and 423 downregulated genes [76]. In particular,
polymorphisms involved in the innate immune system
(CARD9) and cytokine signaling pathways, including TNF,
IL-1, IL-6, and IL-23/IL-17 axes, appear to be strongly as-
sociated with the development of SpA, as per their sug-
gestive effect on Th17-mediated immunity [1, 2].
Epigenetics, the study of mechanisms that determine
and perpetuate heritable genomic functions withoutalteration in the DNA sequence, add to the complexity
of our understanding of the pathogenesis of axSpA.
These changes may account for the heterogeneity of
clinical features and response to targeted therapies ob-
served across patient subgroups [77]. Epigenetics, in-
cluding histone modifications, acetylation, methylation,
phosphorylation, sumoylation, and microRNA, may also
help to explain the influence of environmental risk fac-
tors on genetic variation and their contribution to
phenotypic variation among patients with axSpA [77].
Although multiple studies have demonstrated that
tissue-specific epigenetic modifications play a role in
autoimmune diseases such as rheumatoid arthritis, data
in axSpA remain to be described and validated [77, 78].
Table 1 Genes and gene polymorphisms linked with axSpA
Gene Name Pathway and/or putative function References
Genes and gene polymorphisms
HLA-B27
B2702, 2703, 2704, 2705,
2707, 2708, 2710, 2714,
2715, 2719; 2706 and
2709 (reduced risk)
Human leukocyte antigen B27
105 subtypes encoded by 132
alleles; numerous genetic
risk variants
Peptide presentation to T cells,
HLA-B27 molecule misfolding leading
to endoplasmic reticulum stress reac-
tion, homodimer formation leading
to natural killer (NK) cell activation
Interacts with ERAP1
Caffrey 1973 [141]
Brewerton 1973 [65]
Schlosstein 1973 [66]
Montserrat 2006 [142]
Cipriani 2003 [143]
Yang 2014 [144]
Fiorillo 2003 [145]
Khan 2013 [146]
Jaakkola 2006 [147]
Armas 1999 [148]
Reveille 2006 [149]
HLA-B40, B13, B47, B51
B60, B14
Human leukocyte antigen B Antigen recognition
Interacts with ERAP1
Cortes 2015 [150]
Van Gaalen 2013 [151]
Tumor necrosis factor (TNF) pathway
TNFRSF1A/TNFR1 (383
A/C, rs4149577,
rs4149576, rs1860545,
and rs7954567
polymorphisms)
Tumor necrosis factor receptor
superfamily member 1A
(tumor necrosis factor
receptor 1)
TNF signaling
Nuclear factor (NF)-κB activation and
cytokine production
Corona-Sanchez 2012 [152]
Davidson 2011 [153]
Karaderi 2012 [154]
Evans 2011 [22]
TRADD region on
chromosome 16
Tumor necrosis factor receptor
type 1-associated death domain
TNF signaling
NF-κB activation and cell death
Pointon 2010 [155]
Hsu 1995 [156]
Interleukin 23 pathway
IL-23R (multiple
polymorphisms)
Interleukin-23 receptor gene
Elevated in AS gut epithelium,
from CD 4, γδ T, NK, innate
lymphoid, mast cells
Th17-mediated immunity
Production of IL-17A, IL-17F, IL-22,
and IFN-γ
Reveille 2010 [62]
Burton 2007 [61]
Danoy 2010 [157]
Dong 2013 [158]
Cortes 2013 [159]
Di Cesare 2009 [160]
IL12B (rs6871626,
rs10045431, and
rs3212227
polymorphisms)
Interleukin-12B Activation and differentiation of
IL-23R-expressing cells
Danoy 2010 [157]
Zhang 2015 [161]
Wong 2012 [162]
IL-6R (rs4129267
polymorphism)
Interleukin-6R Th17-mediated immunity
TH17 cell differentiation
Reveille 2015 [75]
Cortes 2013 [159]
IL1R2 (rs2310173
polymorphism)
IL1R1-IL1R2 (rs4851529
and rs2192752
polymorphisms)
Interleukin 1 receptor, type I/II Th17-mediated immunity
Modulation of IL-1 response
Reveille 2010 [62]
Reveille 2015 [75]
JAK2 (rs10758669
polymorphism,
rs1536798/
rs10119004/
rs7857730-CGT
haplotype)
Janus kinase 2 IL-23R signaling molecule Danoy 2010 [157]
Chen 2010 [163]
STAT3 (rs2293152,
rs6503695, rs744166
polymorphisms)
Signal transducer and activator
of transcription 3
IL-23R and IL-6 signaling molecule Davidson 2011 [153]
Danoy 2010 [157]
Lymphocyte development and activation
ERAP1 (multiple
polymorphisms)
Endoplasmic reticulum
aminopeptidase-1
Also pairs with Cw6 of
psoriasis, B51 of Behcet’s, A29
of birdshot chorioretinopathy
but not NOD2 of Crohn’s
Puromycin-sensitive
aminopeptidase
Peptide presentation-Interacts with
HLA-B27 and HLA-B40
Reeves 2014 [164]
Evans 2011 [22]
Abdullah 2015 [165]
Chen 2015 [166]
Bang 2011 [167]
Brown 2016 [168]
TYK2 (rs35164067,
rs6511701, rs280518
Tyrosine kinase 2 Signaling from cytokine receptors,
including IL-23R
Reveille 2015 [75]
Cortes 2013 [159]
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Table 1 Genes and gene polymorphisms linked with axSpA (Continued)
Gene Name Pathway and/or putative function References
polymorphisms)
CARD9 (rs11145835,
rs10781500
polymorphisms)
Caspase recruitment domain
family, member 9
Development of Th17 activation to
some pathogens
Ma 2014 [169]
Evans 2011 [22]
RUNX3 (rs6600247
polymorphism)
Runt-related transcription
factor 3
Reduction in CD8 T cell counts Reveille 2015 [75]
Cortes 2013 [159]
KIR3DL1 Killer immunoglobulin-like
receptor-3 DL1
Inhibits cytotoxicity of NK cells Abdullah 2015 [165]
Zvyagin 2010 [170]
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with each other and their actions are largely dependent
on their cell and tissue context, continuing GWAS may
require specific cell analyses correlating with imaging
and biopsy data to discover pathogenetic effects.
Biologic agents for the treatment of axSpA
The advent of biologic agents has expanded the axSpA
treatment armamentarium. Treatment with biologic
agents is recommended for patients with AS who have
persistently high disease activity despite conventional
treatments [79, 80]. Treatment with biologic agents is also
recommended for patients with nr-axSpA, with the speci-
fication in the European Union that these drugs only be
used in patients with objective signs of inflammation (e.g.,
elevated C-reactive protein [CRP] and/or inflammation of
the sacroiliac joints or spine on MRI) [26].
TNF blockade
The strongest evidence supporting the role of the TNF
pathway in the pathophysiology of axSpA comes from
the use of TNF inhibitors in the clinical setting. TNF in-
hibitors are effective in reducing pain and stiffness and
improving function in patients with AS [81]. TNF inhibi-
tors reduce inflammation in most patients, but may not
provide long-term remission. Recent studies now dem-
onstrate that TNF blockers slow spinal radiographic pro-
gression by reducing disease activity (e.g., based on
changes in the modified Stoke Ankylosing Spondylitis
Spine Score [mSASSS]) [82]. Complete inhibition of
radiographic progression is possible, as evidenced by pa-
tients who have reached an inactive disease state, de-
fined as ASDAS < 1.3; significant reduction in disease
activity is defined as ASDAS < 2.1 [2, 81, 83, 84]. How-
ever, a reported 20% to 30% of patients with axSpA do
not respond adequately to TNF inhibitors, resulting in
the need for other treatment options [85].
For patients who do show an initial response to TNF
inhibition, treatment persistence of 5 years has shown
sustained efficacy and sustained benefits in spinal mobil-
ity, disease activity, physical function, and health-related
quality of life [86, 87]. After 1 year of treatment with
adalimumab, ASAS20 and ASAS40 responses wereachieved by 82% and 62% of patients, respectively, and
after 5 years of treatment with adalimumab, ASAS20
and ASAS40 clinical responses were achieved by 89%
and 70% of patients, respectively [86]. Furthermore,
adalimumab and etanercept increased spine and femoral
neck bone mineral density of patients with active AS
with low bone mineral density [88]. Interestingly, TNF
blockade did not influence the IL-23/Th17 axis, but
TNF blockade did significantly reduce the erythrocyte
sedimentation rate and CRP levels [89].
TNF inhibitors approved for the treatment of AS in-
clude adalimumab, certolizumab pegol, etanercept,
infliximab, and golimumab (Table 2). Adalimumab and
etanercept are also approved for nr-axSpA in Europe,
and certolizumab pegol is approved for nr-axSpA in the
US and Europe. Comparative efficacy analyses indicate
that all five of the approved TNF inhibitors provide
comparable ASAS responses, with similar safety profiles
[90]. Notably, the effects of different TNF inhibitors on
the extra-articular manifestations of axSpA are not
equivalent. For example, infliximab provides better im-
provement in acute anterior uveitis than etanercept and
adalimumab, and etanercept is not an effective treatment
for inflammatory bowel disease [85].
IL-17 blockade
Results of clinical trials aimed at blocking the IL-23/
IL-17 axis in patients with AS support involvement of
this pathway in the pathogenesis of axSpA [2]. As such,
IL-17 has emerged as a novel therapeutic target in AS.
Secukinumab is the only IL-17A inhibitor currently indi-
cated for the treatment of AS (Table 2) [41, 91].
Secukinumab demonstrated efficacy comparable to the
TNF inhibitors clinically in a patient population that in-
cluded both individuals with and without prior exposure
to TNF inhibitors [41, 42]. Secukinumab (10 mg/kg) given
intravenously at weeks 0, 2, and 4, then subcutaneously
(150 mg or 75 mg) every 4 weeks was associated with
ASAS20/40 response rates of 61%/42% compared with
29%/13% with placebo (P < 0.001 for both) at week 16
[42]. When secukinumab was given only subcutaneously,
ASAS20/40 was achieved by 61%/36% and by 41%/26% of
patients treated with secukinumab 150 mg and 75 mg,
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responses were maintained at week 52 [92]. The efficacy
of secukinumab has also been demonstrated over 2 years
in patients who are TNF naïve (ASAS20/40 response rates
at week 104 of 77%/56% with secukinumab 150 mg and
80%/60% with secukinumab 75 mg) [92]. Further, an
observational study of treatment with secukinumab (2 ×
10 mg/kg intravenous loading doses followed by 3 mg/kg
intravenously every 4 weeks for 94 weeks) reported low
progression of spinal radiographic changes with 87% of the
inflammatory vertebral edges and 30% of vertebral edges
with fatty lesions at baseline resolved by week 94 [93].
Ixekizumab, an IL-17 inhibitor in an IgG4 formulation,
has been approved for psoriasis and psoriatic arthritis,
and is under investigation for treatment of AS
(NCT02696785). At 16 weeks, ixekizumab 80 mg every
2 or 4 weeks elicited ASAS 20/40 response rates of 69%/
52% and 64%/48%, respectively, compared with 40%/18%
with placebo (P < 0.01 for all) and 59%/36% with
adalimumab. In addition, there were significant reduc-
tions in spinal inflammation measured by MRI Spondyl-
itis Research Consortium of Canada (SPARCC) spine
score change from baseline [94]. Studies of ixekizumab
(NCT02696798) and the IL-17RA inhibitor brodalumab
(NCT02985983) are ongoing in patients with axSpA.
The dual IL-17A and IL-17F inhibitor, bimekizumab,
has also demonstrated therapeutic potential for the treat-
ment of AS. In a phase 2b study, 12 weeks of treatment
was associated with an ASAS40 response rate of up to
47% compared to 13% with placebo (P < 0.001) [95].
Of great interest would be the use of bispecific bio-
logic therapies that inhibit both TNF and IL-17 [96].
Dual inhibition of these cytokines was more effective at
suppressing arthritis in a collagen-induced arthritis
model than TNF inhibition alone [97].
IL-12/IL-23 blockade
Ustekinumab, a human IgG1κ monoclonal antibody that
binds to the common p40 subunit of IL-12 and IL-23,
failed to meet the primary endpoint of a phase 3 study
in patients with AS naïve to TNF inhibitors
(NCT02437162). At week 24, ASAS40 was achieved by
31% of patients receiving ustekinumab 45 mg, 28% of
patients receiving ustekinumab 90 mg, and 28% of pa-
tients receiving placebo. Additional phase 3 studies of
ustekinumab in AS refractory to TNF inhibitors
(NCT02438787) and nr-axSpA (NCT02407223) were
terminated based on this result [98].
Similarly, risankizumab, a humanized IgG1 monoclo-
nal antibody specific for the IL-23 p19 subunit, failed to
meet the primary endpoint of a phase 2 study in biologic
naïve patients with AS [99]. At week 12, ASAS40 re-
sponse rates were 25% with risankizumab 18 mg, 21%
with risankizumab 90 mg, 15% with risankizumab180 mg, and 18% with placebo. Tildrakizumab, another
IL-23 p19 monoclonal antibody, is in development for
axSpA (NCT02980705). There are no currently
planned studies of the IL-23 p19 monoclonal antibody,
guselkumab, in AS.
The negative results from these studies of ustekinu-
mab and risankizumab were surprising and have led to
speculation about the differing biologic mechanisms that
occur with IL-23 versus IL-17 inhibition. There may be
pathogenic differences between inflammation at spinal
and peripheral sites, possibly related to different mech-
anical load and stress responses of ligament and tendon
insertions through PGE2 activation of ILC3s and pro-
duction of IL-17 via an IL-23–independent pathway
[100]. Of particular interest, recent studies using
single-cell–based technology found that ILC3s were not
a significant source of IL-17 in the joints of patients with
peripheral SpA [101, 102]. It has also been hypothesized
that IL-23 may play a pathogenic role in only certain
stages of axSpA (e.g., during initiation but not estab-
lished disease), suggesting that higher serum concentra-
tions of IL-23 inhibitors may be necessary to have
clinically meaningful effects [100].
JAK blockade
The Janus kinase (JAK)/STAT pathway is thought to ac-
tivate the IL-23/IL-17 cytokine axis, and inhibition of
the JAK-STAT pathway has been proposed as a thera-
peutic strategy in AS [103]. In a phase 2 trial, the JAK 1/
3 inhibitor tofacitinib demonstrated clinical efficacy in
patients with AS [104]. At 12 weeks, tofacitinib 5 mg
BID elicited ASAS20/40 response rates of 81%/46%;
however, placebo responses were also high (41%/20%).
Subanalysis discovered that the best responders were
those with high CRP and higher MRI SPARCC scores.
Indeed, the improvement in SPARCC sacroiliac joint
and spine scores showed a dose response [104].
IL-6 blockade
While serum IL-6 levels have been shown to be elevated
in patients with AS, a recently published phase 2/3 study
failed to demonstrate clinical benefit with tocilizumab, an
IL-6 receptor–targeted monoclonal antibody, in TNF
inhibitor-naïve patients with AS [34]. A related phase 3
trial in patients with AS who had an inadequate response
to previous TNF inhibitor therapy was subsequently ter-
minated (NCT01209689). A phase 2 study of sarilumab,
an IL-6 inhibitor, in TNF inhibitor-naïve patients with ac-
tive AS also failed to show a clinical benefit [105].
IL-1 blockade
The IL-1 receptor family–specifically IL-1β–is a thera-
peutic target for several systemic and local
auto-inflammatory conditions [106]. Two open-label
Table 2 Summary of licensed biologic agents indicated for the treatment of axSpA
Name Mechanism of action Indication Administration Pivotal study Primary endpoint(s) Safety considerations
from prescribing
information
Adalimumab [171] Human IgG1k. Binds
soluble and
transmembrane TNF. All
TNF monoclonal
antibodies can lyse
surface TNF-expressing
cells in vitro in the pres-
ence of complement
US: AS
EU: AS and nr-axSpA
40 mg every other
week
Half-life of ~ 14 days
ABILITY-1 [172] ASAS40 at week 12
• Adalimumab: 36%
(P < 0.001)
• Placebo: 15%
• Serious infections
• Invasive fungal
infections
• Malignancies
• Anaphylaxis or serious
allergic reactions
• Hepatitis B virus
reactivation
• Demyelinating disease
• Cytopenias,
pancytopenia
• Heart failure
• Lupus-like syndrome
Certolizumab pegol
[173]
Fab fragment of
humanized anti-TNF
fused to polyethylene
glycol. Binds to human
TNF-α. Cannot bind to
Fc receptors, fix com-
plement, or cross
placenta
US: AS and nr-axSpA
EU: AS and nr-axSpA
400 mg SC at 1, 2, and
4 weeks, then 200 mg
q2w or 400 mg q4w
Half-life of ~ 14 days
RAPID-axSpA [11] ASAS20 at week 12
• Certolizumab
200 mg Q2W:
58% (P = 0.004)
• Certolizumab
400 mg Q4W:
64% (P < 0.001)
• Placebo: 38%
• Serious infections
• Invasive fungal
infections
• Malignancies
• Anaphylaxis or serious
allergic reactions
• Hepatitis B virus
reactivation
• Demyelinating disease
• Cytopenias,
pancytopenia
• Heart failure
• Lupus-like syndrome
Etanercept [174] Fusion protein of
extracellular-binding
sites of 2 TNF p75 re-
ceptors linked to the Fc
portion of human IgG1.
Binds soluble TNF and
lymphotoxin α (TNF-β)
molecules
US: AS
EU: AS and nr-axSpA
25 mg twice weekly
Half-life of ~ 4 days
Double-blind
randomized
controlled trial [38]
ASAS20 at week 12
• Etanercept: 59%
(P < 0.0001)
• Placebo: 28%
ASAS20 at week 24
• Etanercept: 57%
(P < 0.0001)
• Placebo: 22%
• Serious infections
• Invasive fungal
infections
• Malignancies
• Anaphylaxis or serious
allergic reactions
• Hepatitis B virus
reactivation
• Demyelinating disease
• Cytopenias,
pancytopenia
• Heart failure
• Lupus-like syndrome
Golimumab [175] Human IgG1κ
monoclonal antibody.
Binds soluble and
transmembrane human
TNF-α
US: AS
EU: AS
50 or 100 mg SC once/
month
Half-life of ~ 14 days
GO-RAISE [40] ASAS20 at week 14
• Golimumab
50 mg: 59%
(P < 0.001)
• Golimumab
100 mg: 60%
(P < 0.001)
• Placebo: 22%
• Serious infections
• Invasive fungal
infections
• Malignancies
• Anaphylaxis or serious
allergic reactions
• Hepatitis B virus
reactivation
• Demyelinating disease
• Cytopenias,
pancytopenia
• Heart failure
• Lupus-like syndrome
Infliximab [176] Chimeric mouse-human
monoclonal antibody
with human constant
and murine variable re-
gions. Binds with high
affinity to soluble and
transmembrane TNF-α
US: AS
EU: AS
5 mg/kg at 0, 2 and
6 weeks, then every
6 weeks
Half-life of ~ 9 days
ASSERT [39] ASAS20 at week 24
• Infliximab: 61%
(P < 0.001)
• Placebo: 19%
• Serious infections
• Invasive fungal
infections
• Malignancies
• Anaphylaxis or serious
allergic reactions
• Hepatitis B virus
reactivation
• Demyelinating disease
• Cytopenias,
pancytopenia
• Heart failure
• Lupus-like syndrome
• Hepatotoxicity
• Cardiovascular and
cerebrovascular
reactions
Secukinumab [91] Human anti-IL-17A
monoclonal antibody
US: AS
EU: AS
MEASURE 1: 10 mg/kg
IV at weeks 0, 2, and 4
followed by 75 mg or
MEASURE 1 [42]
MEASURE 2 [42]
MEASURE 1:
ASAS20 at week 16
• Secukinumab
• Serious infections
• Inflammatory bowel
disease
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Table 2 Summary of licensed biologic agents indicated for the treatment of axSpA (Continued)
Name Mechanism of action Indication Administration Pivotal study Primary endpoint(s) Safety considerations
from prescribing
information
150 mg SC Q4W from
week 8
MEASURE 2: 75 mg or
150 mg SC at 0, 1, 2, 3,
and 4 weeks, then Q4W
Half-life of ~ 27 days
75 mg: 60%
(P < 0.001)
• Secukinumab
150 mg: 61%
(P < 0.001)
• Placebo: 29%
MEASURE 2:
ASAS20 at week 16
• Secukinumab
75 mg: 41%
(P = 0.10)
• Secukinumab
150 mg: 61%
(P < 0.001)
• Placebo: 28%
• Anaphylaxis or serious
allergic reactions
q2w every 2 weeks, q4w every 4 weeks, IL, interleukin, nr-axSpA non-radiographic axial spondyloarthritis, SC subcutaneously, TNF tumor necrosis factor
Furst and Louie Arthritis Research & Therapy          (2019) 21:135 Page 9 of 15studies have been conducted to investigate anakinra (an
IL-1–receptor antagonist) in patients with AS. A pilot
study suggested that anakinra may be effective in con-
trolling AS symptoms; however, another study demon-
strated limited improvement in only a small subgroup of
patients with AS [33, 107].
Phosphodiesterase 4 (PDE4) inhibition
A phase 3 randomized, double-blind study of apremilast,
a selective inhibitor of PDE4, did not meet its primary
endpoint of ASAS20 compared with placebo (32.5% vs
36.6%; P = 0.4383) in 490 patients with active AS [108].
Mechanisms of bone formation and loss: Wnt pathway
Both cartilage and diffuse bone loss and pathologic new
bone formation can be observed simultaneously in axSpA
[2]. Mechanisms of inflammation are closely linked with
bone metabolism and elevated levels of pro-inflammatory
cytokines associated with bone loss [109]. Activated T
lymphocytes and osteoblasts express receptor activator of
NF-κB ligand (RANKL), a key regulator of bone remodel-
ing via receptor activator of nuclear factor-κB (RANK)/
RANKL/osteoprotegerin signaling, and both TNF and
IL-1 induce RANKL resulting in bone loss [109]. Three
other important pathways in bone remodeling are the
wingless proteins/Dikkopf-1 (Wnt/DKK-1), secreted
frizzled-related proteins and bone morphogenetic pro-
tein (BMP) pathways, which are affected by inflamma-
tion (Fig. 1) [109–111].
There is a dissociation of TNF-dependent inflammatory
processes and TNF-independent bone-formation pro-
cesses in axSpA, which may be triggered by mechan-
ical and inflammatory stress [112, 113]. Radiographs
are slow in documenting a decrease in new bone for-
mation in patients with AS receiving TNF inhibitors
when compared to historical controls [112, 114], and
recent data with internal controls document less an-
kyloses with TNF inhibitor therapies [6]. MRI recordsdecreases of bone marrow edema that lead to anky-
losis [115] as anti-TNF therapies inhibit in vitro bone
resorption by osteoclast precursor cells generated
from peripheral blood with RANKL [116].
Indeed, TNF inhibitors may passively allow new bone
formation to occur. TNF stimulates expression of
DKK-1, which suppresses signaling by Wnt, a family of
key mediators of osteoblast bone formation [117]. Inhib-
ition of Wnt signaling by DKK promotes osteoblast and
osteoclast formation and differentiation induced by
BMP-2 [118]. These findings suggest that when
anti-TNF therapies reduce inflammation, restoration of
Wnt and BMP pathway signaling may occur, allowing
the potential for new bone formation [2, 83, 119–121].
Additionally, therapeutic approaches are being investi-
gated to activate the Wnt pathway, as antibodies target-
ing sclerostin and DKK-1 have shown promotion of
bone formation and fracture healing for those with
osteoporosis [122].
In animal models, IL-23R+ cells and RORγt+CD4-CD8-
T cells (which are responsive to IL-23) reside in the axial
and peripheral entheseal interface between the tendon
and bone [123–125]. Importantly, in B10.RIII mice, sys-
temic expression of IL-23 sufficiently induced enthesitis
in both the front and back paws without synovial joint
destruction and promoted IL-17 and IL-22 expression
by these entheseal cells. This process required recombin-
ase activating gene (Rag)-dependent cells and occurred
independently of Th17 cells, which is consistent with the
primary role of IL-23 cells in enthesitis. Furthermore,
systemic expression of IL-22 resulted in increased
STAT3 phosphorylation in the bone and induced genes
encoding Wnt family members, BMP, and alkaline phos-
phatase. Together these results indicate that the patho-
physiology of enthesitis is mediated by IL-23 and its
downstream targets, IL-17 and IL-22, whereas IL-22 is
specifically involved in the osteoproliferation component
of the disease [123].
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ASAS classification and response criteria are valuable
tools for most clinicians. However, they are based on
patient-reported outcome measures, including pain, stiff-
ness, fatigue, and patient global assessments, which can
have high levels of both inter- and intra-individual
variability and bias [126]. Thus, use of more objective
measures should be considered in combination with
ASAS criteria.Imaging
Imaging techniques, such as conventional radiography,
bone scintigraphy, MRI, and PDUS, are used for the
diagnosis of axSpA, monitoring disease activity, and
assessing structural damage. Initially, the New York
criteria for diagnosis of AS required radiographic evi-
dence of sacroiliitis [127, 128]. Sacroiliitis appears
only after several years of undiagnosed inflammatory
back pain symptoms, while MRI has demonstrated
that osteitis or bone marrow edema in the sacroiliac
joint is present earlier—before it becomes radiograph-
ically detectable [127, 129]. Thus, MRI is increasingly
being used to detect sacroiliitis early in patients with
axSpA, particularly utilizing coronal and axial se-
quences and high-resolution erosion-specific se-
quences [127, 130–132].
MRI is useful for following therapeutic outcomes.
Anti-TNF with infliximab therapy decreased spinal and
sacroiliac osteitis scores more effectively than nonsteroidal
therapies [133]. Similarly, anti-IL-17A therapy with secu-
kinumab over 2 years decreased spinal osteitis scores and
fatty lesions, which eventuate to ankyloses [93].
PDUS to identify increased vascular flow is also a
highly sensitive and less costly tool for detecting
enthesitis, which is not always detectable by clinical
examination [134]. However, this method is limited
by operator proficiency [125] and its use in sacroilii-
tis needs confirmation. In vivo probing of TNF for
guidance of therapy using 99m Tc-labeled anti-TNF
monoclonal antibodies and specific aptamers are
proposed [135].Serum/tissue biomarkers
Investigations into the discovery of circulating and
tissue-related biomarkers are ongoing. These biomarkers
may help accurately diagnose axSpA, predict disease ac-
tivity/progression, and improve response to therapy. The
most frequently used axSpA marker in the clinical set-
ting for diagnosis is HLA-B27 [136]. Erythrocyte sedi-
mentation rate and CRP are not always dependable
biomarkers for monitoring disease activity, but if ele-
vated, predict better responses to biologic therapies and
more comorbidities. [136]. Other research has focusedon examining the prognostic value of cytokines, particu-
larly IL-17 and IL-23, and downstream matrix metallopro-
teinase (MMP) markers such as MMP-3 (stromelysin-1),
which degrades collagen II, III, IV, IX, X, and the extracel-
lular matrix proteins. Markers of bony metabolism have
also been investigated, including adipokines and cartilage/
connective tissue degradation products [75]. However, no
individual prognostic biomarker for disease activity has
demonstrated adequate reproducibility, and an unmet
need for robust biomarkers remains [75]. Biomarkers from
the specific inflamed sites may be more informative and
descriptive than from peripheral blood samples.Predictive markers
Various biomarkers have been investigated for their pre-
dictive value to treat axSpA. For example, in patients
with axial and peripheral SpA, infliximab treatment re-
sponse is associated with high-sensitivity CRP and cal-
protectin levels [137], while response to golimumab in
patients with AS is associated with various combinations
of markers comprising specific biomarker signatures
[138]. Furthermore, secukinumab response after 6 weeks
of treatment in patients with AS is associated with a de-
crease in levels of S100A8 and S100A9, which form cal-
protectin, the calcium-binding protein used as a marker
of gut inflammation [41].Conclusions
As we learn about the complexities of the pathogenetic
mechanisms that eventuate in axSpA, we cannot be sur-
prised by the different clinical presentations and the
variability of the individual responses to different therap-
ies as the disease progresses over time. Each individual,
possessed with different genetic susceptibilities, will
undergo different initiating factors that will subject their
specific cells to be activated by a varying milieu of
pro-inflammatory and suppressive cytokines, chemo-
kines, and transcriptional factors in different sites.
All agree that early diagnosis of axSpA is important be-
cause earlier treatment provides a more favorable progno-
sis, as irreversible structural damage occurs as the disease
progresses. An early diagnosis of axSpA can also prevent
the use of unnecessary diagnostic procedures and subopti-
mal treatments [139, 140].
Inhibition of TNF, IL-17, and other downstream cyto-
kines and translational factors can reverse spinal inflam-
mation. Careful clinical studies are required to
differentiate if primary non-responders to either TNF or
IL-17 inhibition will respond more effectively to other
classes of therapy. Co-medication with conventional
(NSAIDs) and newer downstream (JAK-STAT) therapies
may be the next therapeutic recommendations to address
the different treatment goals of controlling inflammation
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from the peripheral blood or from localized sites may pre-
dict susceptibility, activity, and clinical response to differ-
ent therapies, but few are consistent and panels may be
required. Accordingly, the current recommendations for
changes to different therapies from knowledgeable investi-
gators will be updated as clinical and translational studies
continue. Thus, it will require careful clinical and imaging
studies, especially in countries with a single medical care
and documentation system, to differentiate whether any of
the individual or combination therapies will modify bone
damage and formation.
Finally, the rheumatologist undertakes the basic re-
sponsibility to educate and communicate, empowering
the patient to be a committed partner in setting thera-
peutic goals, enabling the early referral of primary care
physicians, and collaborating with the referring phys-
ician, therapist, primary care orthopedist, ophthalmolo-
gist, gastroenterologist, and other members of the
healthcare team to promote exercise, smoking cessation,
and high-quality continuing care. Thus, the rheumatolo-
gist who understands the significance of all of the clin-
ical, imaging, genetic, and outcomes data is still the best
decider of individual therapies.
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